The Utility of Advanced Cardiovascular Imaging in Cancer Patients—When, Why, How, and the Latest Developments

Christopher Yu; Faraz Pathan; Timothy C. Tan; Kazuaki Negishi

doi:10.3389/fcvm.2021.728215

The Utility of Advanced Cardiovascular Imaging in Cancer Patients—When, Why, How, and the Latest Developments

Christopher Yu, Faraz Pathan, Timothy C. Tan, Kazuaki Negishi

Research output: Contribution to journal › Short survey › peer-review

8 Citations (Scopus)

Abstract

Cardio-oncology encompasses the risk stratification, prognostication, identification and management of cancer therapeutics related cardiac dysfunction (CTRCD). Cardiovascular imaging (CVI) plays a significant role in each of these scenarios and has broadened from predominantly quantifying left ventricular function (specifically ejection fraction) to the identification of earlier bio-signatures of CTRCD. Recent data also demonstrate the impact of chemotherapy on the right ventricle, left atrium and pericardium and highlight a possible role for CVI in the identification of CTRCD through tissue characterization and assessment of these cardiac chambers. This review aims to provide a contemporary perspective on the role of multi-modal advanced cardiac imaging in cardio-oncology.

Original language	English
Article number	728215
Journal	Frontiers in Cardiovascular Medicine
Volume	8
DOIs	https://doi.org/10.3389/fcvm.2021.728215
Publication status	Published - 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
Copyright © 2021 Yu, Pathan, Tan and Negishi.

Keywords

cancer therapeutics related cardiac dysfunction
cardiac computer tomographic imaging
cardiac imaging
cardiac magnetic resonance imaging
cardio-oncology
cardiotoxicity
echocardiography
global longitudinal strain

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fcvm.2021.728215

Cite this

@article{4efb13dbf76e4fde86f77c6a855bc871,

title = "The Utility of Advanced Cardiovascular Imaging in Cancer Patients—When, Why, How, and the Latest Developments",

abstract = "Cardio-oncology encompasses the risk stratification, prognostication, identification and management of cancer therapeutics related cardiac dysfunction (CTRCD). Cardiovascular imaging (CVI) plays a significant role in each of these scenarios and has broadened from predominantly quantifying left ventricular function (specifically ejection fraction) to the identification of earlier bio-signatures of CTRCD. Recent data also demonstrate the impact of chemotherapy on the right ventricle, left atrium and pericardium and highlight a possible role for CVI in the identification of CTRCD through tissue characterization and assessment of these cardiac chambers. This review aims to provide a contemporary perspective on the role of multi-modal advanced cardiac imaging in cardio-oncology.",

keywords = "cancer therapeutics related cardiac dysfunction, cardiac computer tomographic imaging, cardiac imaging, cardiac magnetic resonance imaging, cardio-oncology, cardiotoxicity, echocardiography, global longitudinal strain",

author = "Christopher Yu and Faraz Pathan and Tan, {Timothy C.} and Kazuaki Negishi",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 Yu, Pathan, Tan and Negishi.",

year = "2021",

doi = "10.3389/fcvm.2021.728215",

language = "English",

volume = "8",

journal = "Frontiers in Cardiovascular Medicine",

issn = "2297-055X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - The Utility of Advanced Cardiovascular Imaging in Cancer Patients—When, Why, How, and the Latest Developments

AU - Yu, Christopher

AU - Pathan, Faraz

AU - Tan, Timothy C.

AU - Negishi, Kazuaki

PY - 2021

Y1 - 2021

N2 - Cardio-oncology encompasses the risk stratification, prognostication, identification and management of cancer therapeutics related cardiac dysfunction (CTRCD). Cardiovascular imaging (CVI) plays a significant role in each of these scenarios and has broadened from predominantly quantifying left ventricular function (specifically ejection fraction) to the identification of earlier bio-signatures of CTRCD. Recent data also demonstrate the impact of chemotherapy on the right ventricle, left atrium and pericardium and highlight a possible role for CVI in the identification of CTRCD through tissue characterization and assessment of these cardiac chambers. This review aims to provide a contemporary perspective on the role of multi-modal advanced cardiac imaging in cardio-oncology.

AB - Cardio-oncology encompasses the risk stratification, prognostication, identification and management of cancer therapeutics related cardiac dysfunction (CTRCD). Cardiovascular imaging (CVI) plays a significant role in each of these scenarios and has broadened from predominantly quantifying left ventricular function (specifically ejection fraction) to the identification of earlier bio-signatures of CTRCD. Recent data also demonstrate the impact of chemotherapy on the right ventricle, left atrium and pericardium and highlight a possible role for CVI in the identification of CTRCD through tissue characterization and assessment of these cardiac chambers. This review aims to provide a contemporary perspective on the role of multi-modal advanced cardiac imaging in cardio-oncology.

KW - cancer therapeutics related cardiac dysfunction

KW - cardiac computer tomographic imaging

KW - cardiac imaging

KW - cardiac magnetic resonance imaging

KW - cardio-oncology

KW - cardiotoxicity

KW - echocardiography

KW - global longitudinal strain

UR - http://www.scopus.com/inward/record.url?scp=85144179655&partnerID=8YFLogxK

U2 - 10.3389/fcvm.2021.728215

DO - 10.3389/fcvm.2021.728215

M3 - Short survey

AN - SCOPUS:85144179655

SN - 2297-055X

VL - 8

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

M1 - 728215

ER -

The Utility of Advanced Cardiovascular Imaging in Cancer Patients—When, Why, How, and the Latest Developments

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this